Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Equities researchers at HC Wainwright upped their Q1 2025 earnings estimates for Legend Biotech in a report issued on Wednesday, March 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their prior forecast of ($0.30). HC Wainwright currently has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech's Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.07) EPS.
Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.46. The business had revenue of $186.50 million for the quarter, compared to analyst estimates of $179.00 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The business's revenue for the quarter was up 134.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.40) earnings per share.
LEGN has been the subject of a number of other reports. Morgan Stanley reduced their target price on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating for the company in a report on Monday. Royal Bank of Canada restated an "outperform" rating and set a $86.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $83.00 price objective on shares of Legend Biotech in a research note on Monday, December 9th. Piper Sandler reaffirmed an "overweight" rating and issued a $78.00 price objective on shares of Legend Biotech in a research note on Monday, December 30th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Legend Biotech in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $79.00.
View Our Latest Research Report on Legend Biotech
Legend Biotech Price Performance
NASDAQ:LEGN traded down $0.60 during trading hours on Monday, reaching $37.49. 373,157 shares of the company's stock were exchanged, compared to its average volume of 1,163,399. The company has a market capitalization of $6.85 billion, a P/E ratio of -39.36 and a beta of 0.19. Legend Biotech has a 12 month low of $30.17 and a 12 month high of $62.78. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27. The business's 50-day simple moving average is $35.94 and its two-hundred day simple moving average is $40.45.
Institutional Investors Weigh In On Legend Biotech
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LEGN. Signaturefd LLC raised its holdings in shares of Legend Biotech by 1,052.7% during the 4th quarter. Signaturefd LLC now owns 1,729 shares of the company's stock valued at $56,000 after purchasing an additional 1,579 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Legend Biotech during the 4th quarter valued at $56,000. Shell Asset Management Co. raised its holdings in shares of Legend Biotech by 62.0% during the 4th quarter. Shell Asset Management Co. now owns 2,090 shares of the company's stock valued at $68,000 after purchasing an additional 800 shares in the last quarter. OFI Invest Asset Management bought a new position in shares of Legend Biotech during the 4th quarter valued at $77,000. Finally, Quadrant Capital Group LLC raised its holdings in shares of Legend Biotech by 4,296.6% during the 4th quarter. Quadrant Capital Group LLC now owns 3,825 shares of the company's stock valued at $124,000 after purchasing an additional 3,738 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company's stock.
Legend Biotech Company Profile
(
Get Free Report)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
See Also
Before you consider Legend Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.
While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
